Comparison of cognitive and UHDRS measures in monitoring disease progression in Huntington's disease: A 12-month longitudinal study

Translational Neurodegeneration

Volumn 3, Issue 1, 2014, Pages

  Toh, Eng A ^a,b   MacAskill, Michael R ^a,b   Dalrymple Alford, John C ^a,b,c   Myall, Daniel J ^b   Livingston, Leslie ^a,b   Macleod, Sandy A D ^d   Anderson, Tim J ^a,b,d  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b NEW ZEALAND BRAIN RESEARCH INSTITUTE   (New Zealand)

^c UNIVERSITY OF CANTERBURY   (New Zealand)

^d CANTERBURY DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

Cognition; Disease progression; Huntington's disease; Longitudinal; UHDRS

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; EXECUTIVE FUNCTION; FEMALE; HUMAN; HUNTINGTON CHOREA; LANGUAGE; LONGITUDINAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MONTREAL COGNITIVE ASSESSMENT; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; UNIFIED HUNTINGTON DISEASE RATING SCALE;

EID: 84904074704     PISSN: None     EISSN: 20479158     Source Type: Journal    
DOI: 10.1186/2047-9158-3-15     Document Type: Article

References (48)

1. Huntington Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983. Huntington Disease Collaborative Research Group.
2. Blackmore L, Simpson SA, Crawford JR. Cognitive performance in UK sample of presymptomatic people carrying the gene for Huntington's disease. J Med Genet 1995, 32:358-362.
3. Duff K, Paulsen J, Mills J, Beglinger LJ, Moser D, Smith MM, Langbehn D, Stout J, Queller S, Harrington DL. Mild cognitive impairment in prediagnosed Huntington disease. Neurology 2010, 75:500-507.
4. Kirkwood SC, Siemers E, Stout JC, Hodes ME, Conneally PM, Christian JC, Foroud T. Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch Neurol 1999, 56:563-568.
5. Peavy GM, Jacobson MW, Goldstein JL, Hamilton JM, Kane A, Gamst AC, Lessig SL, Lee JC, Corey-Bloom J. Cognitive and functional decline in Huntington's disease: dementia criteria revisited. Mov Disord 2010, 25:1163-1169.
6. Bates G, Harper PS, Jones L. Huntington's disease 2002, New York: Oxford University Press.
7. Chodosh J, Petitti DB, Elliott M, Hays RD, Crooks VC, Reuben DB, Galen Buckwalter J, Wenger N. Physician recognition of cognitive impairment: evaluating the need for improvement. J Am Geriatr Soc 2004, 52:1051-1059.
8. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
9. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 1992, 40:922-935.
10. Godefroy O, Fickl A, Roussel M, Auribault C, Bugnicourt JM, Lamy C, Canaple S, Petitnicolas G. Is the Montreal Cognitive Assessment Superior to the Mini-Mental State Examination to Detect Poststroke Cognitive Impairment?: A Study With Neuropsychological Evaluation. Stroke 2011, 42:1712-1716.
11. Scazufca M, Almeida OP, Vallada HP, Tasse WA, Menezes PR. Limitations of the Mini-Mental State Examination for screening dementia in a community with low socioeconomic status: results from the Sao Paulo Ageing & Health Study. Eur Arch Psychiatry Clin Neurosci 2009, 259:8-15.
12. Wind AW, Schellevis FG, Van Staveren G, Scholten RP, Jonker C, Van Eijk JT. Limitations of the Mini-Mental State Examination in diagnosing dementia in general practice. Int J Geriatr Psychiatry 1997, 12:101-108.
13. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005, 53:695-699.
14. Gluhm S, Goldstein J, Brown D, Van Liew C, Gilbert PE, Corey-Bloom J. Usefulness of the Montreal Cognitive Assessment (MoCA) in Huntington's disease. Mov Disord 2013, 28:1744-1747.
15. Videnovic A, Bernard B, Fan W, Jaglin J, Leurgans S, Shannon KM. The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington's disease. Mov Disord 2010, 25:401-404.
16. Mickes L, Jacobson M, Peavy G, Wixted JT, Lessig S, Goldstein JL, Corey-Bloom J. A comparison of two brief screening measures of cognitive impairment in Huntington's disease. Mov Disord 2010, 25:2229-2233.
17. Bezdicek O, Majerova V, Novak M, Nikolai T, Ruzicka E, Roth J. Validity of the Montreal Cognitive Assessment in the detection of cognitive dysfunction in Huntington's disease. Appl Neuropsychol Adult 2013, 20:33-40.
18. Huntington Study Group Unified Huntington's disease rating scale: Reliability and consistency. Movement Disorders 1996, 11:136-142. Huntington Study Group.
19. Sheridan LK, Fitzgerald HE, Adams KM, Nigg JT, Martel MM, Puttler LI, Wong MM, Zucker RA. Normative Symbol Digit Modalities Test performance in a community-based sample. Arch Clin Neuropsychol 2006, 21:23-28.
20. O'Bryant SE, O'Jile JR. Attenuating Demographic Influences on Verbal Fluency and Animal Naming in a Psychiatric Sample. Applied Neuropsychology 2004, 11:208-212.
21. Swanson J. The Delis-Kaplan Executive Function System: A Review. Canadian Journal of School Psychology 2005, 20:117-128.
22. Wechsler D. Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) administration and scoring manual 2008, San Antonio, TX: Psychological Corporation.
23. Smith A. Symbol Digit Modalities Test Manual 2007, Western Psychological Services: Torrance, CA.
24. Ruff RM, Niemann H, Allen CC, Farrow CE, Wylie T. The Ruff 2 and 7 Selective Attention Test: a neuropsychological application. Percept Mot Skills 1992, 75:1311-1319.
25. Graves RE, Bezeau SC, Fogarty J, Blair R. Boston naming test short forms: a comparison of previous forms with new item response theory based forms. J Clin Exp Neuropsychol 2004, 26:891-902.
26. Unverzagt FW, Morgan OS, Thesiger CH, Eldemire DA, Luseko J, Pokuri S, Hui SL, Hall KS, Hendrie HC. Clinical utility of CERAD neuropsychological battery in elderly Jamaicans. J Int Neuropsychol Soc 1999, 5:255-259.
27. Dalrymple-Alford JC, Livingston L, MacAskill MR, Graham C, Melzer TR, Porter RJ, Watts R, Anderson TJ. Characterizing mild cognitive impairment in Parkinson's disease. Mov Disord 2011, 26:629-636.
28. Gelman A, Hill J. Data analysis using regression and multilevel/hierarchical models 2007, New York: Cambridge University Press.
29. Efron B. Bootstrap Methods: Another Look at the Jackknife. The Annals of Statistics 1979, 7:1-26.
30. Tabrizi SJ, Scahill RI, Durr A, Roos RAC, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. The Lancet Neurology 2010, 10:31-42.
31. Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012, 11:42-53.
32. Bachoud-Levi AC, Maison P, Bartolomeo P, Boisse MF, Dalla Barba G, Ergis AM, Baudic S, Degos JD, Cesaro P, Peschanski M. Retest effects and cognitive decline in longitudinal follow-up of patients with early HD. Neurology 2001, 56:1052-1058.
33. Snowden J, Craufurd D, Griffiths H, Thompson J, Neary D. Longitudinal evaluation of cognitive disorder in Huntington's disease. J Int Neuropsychol Soc 2001, 7:33-44.
34. Lawrence AD, Sahakian BJ, Hodges JR, Rosser AE, Lange KW, Robbins TW. Executive and mnemonic functions in early Huntington's disease. Brain 1996, 119(Pt 5):1633-1645.
35. Ho AK, Sahakian BJ, Brown RG, Barker RA, Hodges JR, Ane MN, Snowden J, Thompson J, Esmonde T, Gentry R, Moore JW, Bodner T. Profile of cognitive progression in early Huntington's disease. Neurology 2003, 61:1702-1706.
36. Lemiere J, Decruyenaere M, Evers-Kiebooms G, Vandenbussche E, Dom R. Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation-a longitudinal follow-up study. J Neurol 2004, 251:935-942.
37. McCaffrey RJ, Westervelt HJ. Issues associated with repeated neuropsychological assessments. Neuropsychol Rev 1995, 5:203-221.
38. Salthouse TA, Tucker-Drob EM. Implications of short-term retest effects for the interpretation of longitudinal change. Neuropsychology 2008, 22:800-811.
39. Collie A, Maruff P, Darby DG, McStephen M. The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc 2003, 9:419-428.
40. Falleti MG, Maruff P, Collie A, Darby DG. Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals. J Clin Exp Neuropsychol 2006, 28:1095-1112.
41. Bartels C, Wegrzyn M, Wiedl A, Ackermann V, Ehrenreich H. Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing. BMC Neurosci 2010, 11:118.
42. Roth J, Klempii J, Jech R, Zidovska J, Uhrova T, Doubek P, Ulmanova O, Brozova H, Volfova M, Serranova T, Ruzicka E. Caudate nucleus atrophy in Huntington's disease and its relationship with clinical and genetic parameters. Funct Neurol 2005, 20:127-130.
43. Bowie P, Branton T, Holmes J. Should the Mini Mental State Examination be used to monitor dementia treatments?. The Lancet 1999, 354:1527-1528.
44. Clark CM, Sheppard L, Fillenbaum GG, Galasko D, Morris JC, Koss E, Mohs R, Heyman A. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol 1999, 56:857-862.
45. Larner AJ, Julayanont P, Phillips N, Chertkow H, Nasreddine Z. Montreal Cognitive Assessment (MoCA): Concept and Clinical Review. Cognitive Screening Instruments 2013, 111-151. London: Springer.
46. Jauhar S, Ritchie S. Psychiatric and behavioural manifestations of Huntington's disease. Advances in Psychiatric Treatment 2010, 16:168-175.
47. Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. Mov Disord 2008, 23:1491-1504.
48. Rao AK, Gordon AM, Marder KS. Coordination of fingertip forces during precision grip in premanifest Huntington's disease. Mov Disord 2011, 26:862-869.